WordPress database error: [The table 'wp_options' is full] UPDATE `wp_options` SET `option_value` = 'a:15:{s:21:\"id_slug_type_path_map\";a:1:{i:1431;a:3:{s:4:\"slug\";s:16:\"ilab-media-tools\";s:4:\"type\";s:6:\"plugin\";s:4:\"path\";s:37:\"ilab-media-tools/ilab-media-tools.php\";}}s:11:\"plugin_data\";a:1:{s:16:\"ilab-media-tools\";a:30:{s:16:\"plugin_main_file\";O:8:\"stdClass\":1:{s:4:\"path\";s:37:\"ilab-media-tools/ilab-media-tools.php\";}s:20:\"is_network_activated\";b:0;s:17:\"install_timestamp\";i:1590575783;s:17:\"was_plugin_loaded\";b:1;s:21:\"is_plugin_new_install\";b:0;s:16:\"sdk_last_version\";s:5:\"2.6.2\";s:11:\"sdk_version\";s:5:\"2.7.0\";s:16:\"sdk_upgrade_mode\";b:1;s:18:\"sdk_downgrade_mode\";b:0;s:19:\"plugin_last_version\";s:5:\"4.6.2\";s:14:\"plugin_version\";s:5:\"4.6.4\";s:19:\"plugin_upgrade_mode\";b:1;s:21:\"plugin_downgrade_mode\";b:0;s:17:\"connectivity_test\";a:6:{s:12:\"is_connected\";b:1;s:4:\"host\";s:16:\"virusreports.net\";s:9:\"server_ip\";s:12:\"91.187.95.36\";s:9:\"is_active\";b:1;s:9:\"timestamp\";i:1590575783;s:7:\"version\";s:6:\"3.3.21\";}s:15:\"prev_is_premium\";b:0;s:12:\"is_anonymous\";a:3:{s:2:\"is\";b:1;s:9:\"timestamp\";i:1590575802;s:7:\"version\";s:6:\"3.3.21\";}s:14:\"has_trial_plan\";b:0;s:22:\"install_sync_timestamp\";i:1669820589;s:19:\"keepalive_timestamp\";i:1669820589;s:16:\"last_license_key\";s:32:\"29a39c221b0aa00cce0f4662daf6542b\";s:20:\"last_license_user_id\";N;s:15:\"is_whitelabeled\";b:0;s:20:\"activation_timestamp\";i:1590576202;s:13:\"subscriptions\";a:1:{i:0;O:15:\"FS_Subscription\":20:{s:2:\"id\";s:6:\"104441\";s:7:\"updated\";s:19:\"2020-05-27 11:18:22\";s:7:\"created\";s:19:\"2020-05-27 10:43:19\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:7:\"user_id\";s:7:\"3108640\";s:10:\"install_id\";s:7:\"4721959\";s:7:\"plan_id\";s:4:\"4634\";s:10:\"license_id\";s:6:\"360855\";s:11:\"total_gross\";d:8.99;s:16:\"amount_per_cycle\";d:8.99;s:13:\"billing_cycle\";i:1;s:19:\"outstanding_balance\";i:0;s:15:\"failed_payments\";i:0;s:7:\"gateway\";s:6:\"paypal\";s:11:\"external_id\";s:14:\"I-GS60RRYM35BC\";s:10:\"trial_ends\";N;s:12:\"next_payment\";N;s:11:\"canceled_at\";s:19:\"2020-05-27 11:18:22\";s:6:\"vat_id\";N;s:12:\"country_code\";s:2:\"ad\";}}s:9:\"beta_data\";a:2:{s:7:\"is_beta\";b:0;s:7:\"version\";s:6:\"3.3.23\";}s:14:\"sync_timestamp\";i:1669820589;s:9:\"sync_cron\";O:8:\"stdClass\":5:{s:7:\"version\";s:6:\"3.3.21\";s:7:\"blog_id\";i:0;s:11:\"sdk_version\";s:5:\"2.3.1\";s:9:\"timestamp\";i:1590580984;s:2:\"on\";b:1;}s:21:\"trial_promotion_shown\";i:1593702258;s:30:\"affiliate_program_notice_shown\";i:1593702258;s:19:\"last_load_timestamp\";i:1788605113;}}s:13:\"file_slug_map\";a:2:{s:37:\"ilab-media-tools/ilab-media-tools.php\";s:16:\"ilab-media-tools\";s:45:\"ilab-media-tools-premium/ilab-media-tools.php\";s:16:\"ilab-media-tools\";}s:7:\"plugins\";a:1:{s:16:\"ilab-media-tools\";O:9:\"FS_Plugin\":24:{s:2:\"id\";s:4:\"1431\";s:7:\"updated\";N;s:7:\"created\";N;s:22:\"\0FS_Entity\0_is_updated\";b:1;s:10:\"public_key\";s:32:\"pk_f20e8088bc078daafd3a20b6f653d\";s:10:\"secret_key\";N;s:16:\"parent_plugin_id\";N;s:5:\"title\";s:11:\"Media Cloud\";s:4:\"slug\";s:16:\"ilab-media-tools\";s:12:\"premium_slug\";s:24:\"ilab-media-tools-premium\";s:4:\"type\";s:6:\"plugin\";s:20:\"affiliate_moderation\";s:8:\"selected\";s:19:\"is_wp_org_compliant\";b:1;s:22:\"premium_releases_count\";N;s:4:\"file\";s:37:\"ilab-media-tools/ilab-media-tools.php\";s:7:\"version\";s:5:\"4.6.4\";s:11:\"auto_update\";N;s:4:\"info\";N;s:10:\"is_premium\";b:0;s:14:\"premium_suffix\";s:9:\"(Premium)\";s:7:\"is_live\";b:1;s:9:\"bundle_id\";N;s:17:\"bundle_public_key\";N;s:17:\"opt_in_moderation\";N;}}s:9:\"unique_id\";s:32:\"76bc5468b0fafc3e561fa1535364edb6\";s:5:\"plans\";a:1:{s:16:\"ilab-media-tools\";a:7:{i:0;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"MjA1NQ==\";s:7:\"updated\";s:28:\"MjAxOS0wMS0yMCAxNTowNjo0Mg==\";s:7:\"created\";s:28:\"MjAxNy0wOS0zMCAwOTozOToxNg==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:8:\"ZnJlZQ==\";s:5:\"title\";s:8:\"RnJlZQ==\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";N;s:13:\"support_forum\";N;s:13:\"support_email\";N;s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:1;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NDYzMg==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNDowMg==\";s:7:\"created\";s:28:\"MjAxOC0xMi0wOSAxNzowNTozMw==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:8:\"YmFzaWM=\";s:5:\"title\";s:8:\"QmFzaWM=\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:0:\"\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:4:\"MQ==\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"aGVscEBtZWRpYWNsb3VkLnByZXNz\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:2;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NzA2MA==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNDo0Ng==\";s:7:\"created\";s:28:\"MjAxOS0wOC0xNiAxODoyNzowMQ==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:20:\"bXVsdGlzaXRlX2Jhc2lj\";s:5:\"title\";s:20:\"TXVsdGlzaXRlIEJhc2lj\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3Mv\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"aGVscEBtZWRpYWNsb3VkLnByZXNz\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:3;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NDYzNA==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyMzoyMA==\";s:7:\"created\";s:28:\"MjAxOC0xMi0wOSAxNzowOToxOA==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:4:\"cHJv\";s:5:\"title\";s:4:\"UHJv\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:0:\"\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:4:\"MQ==\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"aGVscEBtZWRpYWNsb3VkLnByZXNz\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:4:\"MQ==\";s:9:\"is_hidden\";N;}i:4;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NzIxNg==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNToxNQ==\";s:7:\"created\";s:28:\"MjAxOS0wOC0yOSAwNDo0NDoxMA==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:20:\"bXVsdGlzaXRlX3Bybw==\";s:5:\"title\";s:20:\"TXVsdGlzaXRlIFBybw==\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"am9uQGludGVyZmFjZWxhYi5jb20=\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:5;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NzIxNw==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNTozOA==\";s:7:\"created\";s:28:\"MjAxOS0wOC0yOSAwNDo1MDoxOQ==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:28:\"bXVsdGlzaXRlX3VubGltaXRlZA==\";s:5:\"title\";s:28:\"TXVsdGlzaXRlIFVubGltaXRlZA==\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"am9uQGludGVyZmFjZWxhYi5jb20=\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:6;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NDYzNQ==\";s:7:\"updated\";s:28:\"MjAyMC0wOS0wNCAxNzoyNToxNg==\";s:7:\"created\";s:28:\"MjAxOC0xMi0wOSAxNzoxODoyMw==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:8:\"YWdlbmN5\";s:5:\"title\";s:8:\"QWdlbmN5\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:0:\"\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:4:\"MQ==\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"am9uQGludGVyZmFjZWxhYi5jb20=\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:4:\"MQ==\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}}}s:14:\"active_plugins\";O:8:\"stdClass\":3:{s:9:\"timestamp\";i:1615474488;s:3:\"md5\";s:32:\"1e32a299fdcdafa009ca51c5cb9bc76c\";s:7:\"plugins\";a:23:{s:19:\"akismet/akismet.php\";a:5:{s:4:\"slug\";s:7:\"akismet\";s:7:\"version\";s:5:\"4.1.5\";s:5:\"title\";s:17:\"Akismet Anti-Spam\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:11:\"amp/amp.php\";a:5:{s:4:\"slug\";s:3:\"amp\";s:7:\"version\";s:5:\"1.5.3\";s:5:\"title\";s:3:\"AMP\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:63:\"www-xml-sitemap-generator-org/www-xml-sitemap-generator-org.php\";a:5:{s:4:\"slug\";s:29:\"www-xml-sitemap-generator-org\";s:7:\"version\";s:5:\"1.3.4\";s:5:\"title\";s:28:\"Google XML Sitemap Generator\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:65:\"newsomatic-news-post-generator/newsomatic-news-post-generator.php\";a:5:{s:4:\"slug\";s:30:\"newsomatic-news-post-generator\";s:7:\"version\";s:5:\"2.4.4\";s:5:\"title\";s:35:\"Newsomatic Automatic Post Generator\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:57:\"ssl-insecure-content-fixer/ssl-insecure-content-fixer.php\";a:5:{s:4:\"slug\";s:26:\"ssl-insecure-content-fixer\";s:7:\"version\";s:5:\"2.7.2\";s:5:\"title\";s:26:\"SSL Insecure Content Fixer\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"td-cloud-library/td-cloud-library.php\";a:5:{s:4:\"slug\";s:16:\"td-cloud-library\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Cloud Library\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:27:\"td-composer/td-composer.php\";a:5:{s:4:\"slug\";s:11:\"td-composer\";s:7:\"version\";s:31:\"2.6 | built on 06.05.2020 14:38\";s:5:\"title\";s:15:\"tagDiv Composer\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"td-mobile-plugin/td-mobile-plugin.php\";a:5:{s:4:\"slug\";s:16:\"td-mobile-plugin\";s:7:\"version\";s:31:\"1.4 | built on 06.05.2020 14:38\";s:5:\"title\";s:19:\"tagDiv Mobile Theme\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:31:\"td-newsletter/td-newsletter.php\";a:5:{s:4:\"slug\";s:13:\"td-newsletter\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:17:\"tagDiv Newsletter\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:39:\"td-social-counter/td-social-counter.php\";a:5:{s:4:\"slug\";s:17:\"td-social-counter\";s:7:\"version\";s:31:\"4.7 | built on 06.05.2020 14:38\";s:5:\"title\";s:21:\"tagDiv Social Counter\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"td-standard-pack/td-standard-pack.php\";a:5:{s:4:\"slug\";s:16:\"td-standard-pack\";s:7:\"version\";s:36:\"1.0 BETA | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Standard Pack\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:81:\"update-theme-and-plugins-from-zip-file/update-theme-and-plugins-from-zip-file.php\";a:5:{s:4:\"slug\";s:38:\"update-theme-and-plugins-from-zip-file\";s:7:\"version\";s:5:\"1.1.1\";s:5:\"title\";s:38:\"Update Theme and Plugins from Zip File\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:31:\"wp-statistics/wp-statistics.php\";a:5:{s:4:\"slug\";s:13:\"wp-statistics\";s:7:\"version\";s:7:\"12.6.13\";s:5:\"title\";s:13:\"WP Statistics\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"ilab-media-tools/ilab-media-tools.php\";a:15:{s:4:\"Name\";s:11:\"Media Cloud\";s:9:\"PluginURI\";s:48:\"https://github.com/interfacelab/ilab-media-tools\";s:7:\"Version\";s:6:\"3.3.21\";s:11:\"Description\";s:150:\"Automatically upload media to Amazon S3 and integrate with Imgix, a real-time image processing CDN. Boosts site performance and simplifies workflows.\";s:6:\"Author\";s:12:\"interfacelab\";s:9:\"AuthorURI\";s:22:\"http://interfacelab.io\";s:10:\"TextDomain\";s:16:\"ilab-media-tools\";s:10:\"DomainPath\";s:0:\"\";s:7:\"Network\";b:0;s:10:\"RequiresWP\";s:0:\"\";s:11:\"RequiresPHP\";s:0:\"\";s:5:\"Title\";s:11:\"Media Cloud\";s:10:\"AuthorName\";s:12:\"interfacelab\";s:9:\"is_active\";b:1;s:4:\"slug\";s:16:\"ilab-media-tools\";}s:29:\"a3-lazy-load/a3-lazy-load.php\";a:5:{s:4:\"slug\";s:12:\"a3-lazy-load\";s:7:\"version\";s:5:\"2.3.2\";s:5:\"title\";s:12:\"a3 Lazy Load\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:49:\"autoremove-attachments/autoremove-attachments.php\";a:5:{s:4:\"slug\";s:22:\"autoremove-attachments\";s:7:\"version\";s:5:\"1.1.2\";s:5:\"title\";s:22:\"Autoremove Attachments\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:43:\"remove-category-url/remove-category-url.php\";a:5:{s:4:\"slug\";s:19:\"remove-category-url\";s:7:\"version\";s:5:\"1.1.6\";s:5:\"title\";s:19:\"Remove Category URL\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:74:\"wp-404-auto-redirect-to-similar-post/wp-404-auto-redirect-similar-post.php\";a:5:{s:4:\"slug\";s:36:\"wp-404-auto-redirect-to-similar-post\";s:7:\"version\";s:5:\"1.0.3\";s:5:\"title\";s:36:\"WP 404 Auto Redirect to Similar Post\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:27:\"wp-super-cache/wp-cache.php\";a:5:{s:4:\"slug\";s:14:\"wp-super-cache\";s:7:\"version\";s:5:\"1.7.1\";s:5:\"title\";s:14:\"WP Super Cache\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:31:\"ninjafirewall/ninjafirewall.php\";a:5:{s:4:\"slug\";s:13:\"ninjafirewall\";s:7:\"version\";s:5:\"4.2.5\";s:5:\"title\";s:26:\"NinjaFirewall (WP Edition)\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:55:\"remove-yoast-seo-comments/remove-yoast-seo-comments.php\";a:5:{s:4:\"slug\";s:25:\"remove-yoast-seo-comments\";s:7:\"version\";s:3:\"3.1\";s:5:\"title\";s:25:\"Remove Yoast SEO Comments\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:39:\"simple-wp-sitemap/simple-wp-sitemap.php\";a:5:{s:4:\"slug\";s:17:\"simple-wp-sitemap\";s:7:\"version\";s:5:\"1.2.1\";s:5:\"title\";s:17:\"Simple Wp Sitemap\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:24:\"wordpress-seo/wp-seo.php\";a:5:{s:4:\"slug\";s:13:\"wordpress-seo\";s:7:\"version\";s:4:\"15.0\";s:5:\"title\";s:9:\"Yoast SEO\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}}}s:11:\"all_plugins\";O:8:\"stdClass\":3:{s:9:\"timestamp\";i:1610722496;s:3:\"md5\";s:32:\"1ff5e8068ccc517ab9df7827a605c79e\";s:7:\"plugins\";a:24:{s:19:\"akismet/akismet.php\";a:6:{s:4:\"slug\";s:7:\"akismet\";s:7:\"version\";s:5:\"4.1.5\";s:5:\"title\";s:17:\"Akismet Anti-Spam\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"4.1.8\";}s:11:\"amp/amp.php\";a:6:{s:4:\"slug\";s:3:\"amp\";s:7:\"version\";s:5:\"1.5.3\";s:5:\"title\";s:3:\"AMP\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"2.0.10\";}s:63:\"www-xml-sitemap-generator-org/www-xml-sitemap-generator-org.php\";a:6:{s:4:\"slug\";s:29:\"www-xml-sitemap-generator-org\";s:7:\"version\";s:5:\"1.3.4\";s:5:\"title\";s:28:\"Google XML Sitemap Generator\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"1.3.5\";}s:37:\"ilab-media-tools/ilab-media-tools.php\";a:6:{s:4:\"slug\";s:16:\"ilab-media-tools\";s:7:\"version\";s:6:\"3.3.21\";s:5:\"title\";s:11:\"Media Cloud\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"4.1.14\";}s:65:\"newsomatic-news-post-generator/newsomatic-news-post-generator.php\";a:6:{s:4:\"slug\";s:30:\"newsomatic-news-post-generator\";s:7:\"version\";s:5:\"2.4.4\";s:5:\"title\";s:35:\"Newsomatic Automatic Post Generator\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:7:\"3.0.1.3\";}s:57:\"ssl-insecure-content-fixer/ssl-insecure-content-fixer.php\";a:5:{s:4:\"slug\";s:26:\"ssl-insecure-content-fixer\";s:7:\"version\";s:5:\"2.7.2\";s:5:\"title\";s:26:\"SSL Insecure Content Fixer\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:37:\"td-cloud-library/td-cloud-library.php\";a:6:{s:4:\"slug\";s:16:\"td-cloud-library\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Cloud Library\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:30:\"1.5 | built on 17.06.2020 8:12\";}s:27:\"td-composer/td-composer.php\";a:6:{s:4:\"slug\";s:11:\"td-composer\";s:7:\"version\";s:31:\"2.6 | built on 06.05.2020 14:38\";s:5:\"title\";s:15:\"tagDiv Composer\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:30:\"2.6 | built on 17.06.2020 8:12\";}s:37:\"td-mobile-plugin/td-mobile-plugin.php\";a:6:{s:4:\"slug\";s:16:\"td-mobile-plugin\";s:7:\"version\";s:31:\"1.4 | built on 06.05.2020 14:38\";s:5:\"title\";s:19:\"tagDiv Mobile Theme\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:30:\"1.4 | built on 17.06.2020 8:12\";}s:31:\"td-newsletter/td-newsletter.php\";a:5:{s:4:\"slug\";s:13:\"td-newsletter\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:17:\"tagDiv Newsletter\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:39:\"td-social-counter/td-social-counter.php\";a:5:{s:4:\"slug\";s:17:\"td-social-counter\";s:7:\"version\";s:31:\"4.7 | built on 06.05.2020 14:38\";s:5:\"title\";s:21:\"tagDiv Social Counter\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:37:\"td-standard-pack/td-standard-pack.php\";a:5:{s:4:\"slug\";s:16:\"td-standard-pack\";s:7:\"version\";s:36:\"1.0 BETA | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Standard Pack\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:81:\"update-theme-and-plugins-from-zip-file/update-theme-and-plugins-from-zip-file.php\";a:6:{s:4:\"slug\";s:38:\"update-theme-and-plugins-from-zip-file\";s:7:\"version\";s:5:\"1.1.1\";s:5:\"title\";s:38:\"Update Theme and Plugins from Zip File\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"2.0.0\";}s:31:\"wp-statistics/wp-statistics.php\";a:6:{s:4:\"slug\";s:13:\"wp-statistics\";s:7:\"version\";s:7:\"12.6.13\";s:5:\"title\";s:13:\"WP Statistics\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"13.0.5\";}s:49:\"wp-statistics-rest-api/wp-statistics-rest-api.php\";a:5:{s:4:\"slug\";s:22:\"wp-statistics-rest-api\";s:7:\"version\";s:5:\"1.2.2\";s:5:\"title\";s:24:\"WP Statistics - REST API\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:29:\"a3-lazy-load/a3-lazy-load.php\";a:6:{s:4:\"slug\";s:12:\"a3-lazy-load\";s:7:\"version\";s:5:\"2.3.2\";s:5:\"title\";s:12:\"a3 Lazy Load\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"2.4.3\";}s:49:\"autoremove-attachments/autoremove-attachments.php\";a:6:{s:4:\"slug\";s:22:\"autoremove-attachments\";s:7:\"version\";s:5:\"1.1.2\";s:5:\"title\";s:22:\"Autoremove Attachments\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"1.2.1\";}s:43:\"remove-category-url/remove-category-url.php\";a:5:{s:4:\"slug\";s:19:\"remove-category-url\";s:7:\"version\";s:5:\"1.1.6\";s:5:\"title\";s:19:\"Remove Category URL\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:74:\"wp-404-auto-redirect-to-similar-post/wp-404-auto-redirect-similar-post.php\";a:5:{s:4:\"slug\";s:36:\"wp-404-auto-redirect-to-similar-post\";s:7:\"version\";s:5:\"1.0.3\";s:5:\"title\";s:36:\"WP 404 Auto Redirect to Similar Post\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:27:\"wp-super-cache/wp-cache.php\";a:5:{s:4:\"slug\";s:14:\"wp-super-cache\";s:7:\"version\";s:5:\"1.7.1\";s:5:\"title\";s:14:\"WP Super Cache\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:31:\"ninjafirewall/ninjafirewall.php\";a:6:{s:4:\"slug\";s:13:\"ninjafirewall\";s:7:\"version\";s:5:\"4.2.5\";s:5:\"title\";s:26:\"NinjaFirewall (WP Edition)\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"4.3.1\";}s:55:\"remove-yoast-seo-comments/remove-yoast-seo-comments.php\";a:5:{s:4:\"slug\";s:25:\"remove-yoast-seo-comments\";s:7:\"version\";s:3:\"3.1\";s:5:\"title\";s:25:\"Remove Yoast SEO Comments\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:39:\"simple-wp-sitemap/simple-wp-sitemap.php\";a:5:{s:4:\"slug\";s:17:\"simple-wp-sitemap\";s:7:\"version\";s:5:\"1.2.1\";s:5:\"title\";s:17:\"Simple Wp Sitemap\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:24:\"wordpress-seo/wp-seo.php\";a:6:{s:4:\"slug\";s:13:\"wordpress-seo\";s:7:\"version\";s:4:\"15.0\";s:5:\"title\";s:9:\"Yoast SEO\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"15.6.2\";}}}s:10:\"all_themes\";O:8:\"stdClass\":3:{s:9:\"timestamp\";i:1615474488;s:3:\"md5\";s:32:\"c7608adb62521fe1c683d1fdd1039cf9\";s:6:\"themes\";a:1:{s:9:\"Newspaper\";a:5:{s:4:\"slug\";s:9:\"Newspaper\";s:7:\"version\";s:6:\"10.3.5\";s:5:\"title\";s:9:\"Newspaper\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}}}s:5:\"sites\";a:1:{s:16:\"ilab-media-tools\";O:7:\"FS_Site\":26:{s:2:\"id\";s:7:\"4721959\";s:7:\"updated\";s:19:\"2022-11-11 15:49:12\";s:7:\"created\";s:19:\"2020-05-27 10:43:17\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:10:\"public_key\";s:32:\"pk_6e950b674c6966af990cfa14cff7d\";s:10:\"secret_key\";s:32:\"sk_J}Yv][+DKV$b?j1Qoh3aj*?5FO78K\";s:7:\"site_id\";s:8:\"29644807\";s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:5:\"title\";s:12:\"Virus Report\";s:3:\"url\";s:24:\"https://virusreports.net\";s:7:\"version\";s:6:\"4.5.11\";s:8:\"language\";s:5:\"en-US\";s:16:\"platform_version\";s:5:\"5.8.6\";s:11:\"sdk_version\";s:5:\"2.4.5\";s:28:\"programming_language_version\";s:6:\"7.4.30\";s:7:\"plan_id\";s:4:\"2055\";s:10:\"license_id\";N;s:13:\"trial_plan_id\";N;s:10:\"trial_ends\";N;s:10:\"is_premium\";b:0;s:15:\"is_disconnected\";b:0;s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;s:7:\"is_beta\";b:0;s:7:\"charset\";s:5:\"UTF-8\";}}s:5:\"users\";a:1:{i:3108640;O:7:\"FS_User\":13:{s:2:\"id\";s:7:\"3108640\";s:7:\"updated\";s:19:\"2020-05-27 10:43:19\";s:7:\"created\";s:19:\"2020-05-27 10:43:16\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:10:\"public_key\";s:32:\"pk_d59257bb9e82a4b8e004a8c305a03\";s:10:\"secret_key\";s:32:\"sk_[~lJoxs51=yv_[!0boAFtR!qH^N88\";s:5:\"email\";s:16:\"vizboo@yahoo.com\";s:5:\"first\";s:6:\"vizboo\";s:4:\"last\";s:2:\"yu\";s:11:\"is_verified\";b:0;s:11:\"customer_id\";N;s:5:\"gross\";i:0;s:7:\"is_beta\";b:0;}}s:23:\"user_id_license_ids_map\";a:1:{i:1431;a:1:{i:3108640;a:3:{i:0;i:360876;i:1;i:360858;i:2;i:360855;}}}s:12:\"all_licenses\";a:1:{i:1431;a:3:{i:0;O:17:\"FS_Plugin_License\":21:{s:2:\"id\";s:6:\"360876\";s:7:\"updated\";s:19:\"2020-06-08 11:08:49\";s:7:\"created\";s:19:\"2020-05-27 11:00:50\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:7:\"plan_id\";s:4:\"4634\";s:16:\"parent_plan_name\";N;s:17:\"parent_plan_title\";N;s:17:\"parent_license_id\";N;s:8:\"products\";N;s:10:\"pricing_id\";s:4:\"3792\";s:5:\"quota\";i:1;s:9:\"activated\";i:1;s:15:\"activated_local\";i:0;s:10:\"expiration\";s:19:\"2020-06-08 10:08:49\";s:10:\"secret_key\";s:32:\"sk_3sFp^Ov>pTgwHb!j6jnt0}=96-Ss;\";s:15:\"is_whitelabeled\";b:0;s:17:\"is_free_localhost\";b:1;s:17:\"is_block_features\";b:1;s:12:\"is_cancelled\";b:1;}i:1;O:17:\"FS_Plugin_License\":21:{s:2:\"id\";s:6:\"360858\";s:7:\"updated\";s:19:\"2020-05-27 11:00:50\";s:7:\"created\";s:19:\"2020-05-27 10:48:38\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:7:\"plan_id\";s:4:\"4634\";s:16:\"parent_plan_name\";N;s:17:\"parent_plan_title\";N;s:17:\"parent_license_id\";N;s:8:\"products\";N;s:10:\"pricing_id\";s:4:\"3792\";s:5:\"quota\";i:1;s:9:\"activated\";i:0;s:15:\"activated_local\";i:0;s:10:\"expiration\";s:19:\"2020-06-27 10:00:00\";s:10:\"secret_key\";s:32:\"sk_OH_+BJ<*Hk<QjK{L*oIu{quIxpo4y\";s:15:\"is_whitelabeled\";b:0;s:17:\"is_free_localhost\";b:1;s:17:\"is_block_features\";b:1;s:12:\"is_cancelled\";b:0;}i:2;O:17:\"FS_Plugin_License\":21:{s:2:\"id\";s:6:\"360855\";s:7:\"updated\";s:19:\"2020-06-27 14:55:34\";s:7:\"created\";s:19:\"2020-05-27 10:43:19\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:7:\"plan_id\";s:4:\"4634\";s:16:\"parent_plan_name\";N;s:17:\"parent_plan_title\";N;s:17:\"parent_license_id\";N;s:8:\"products\";N;s:10:\"pricing_id\";s:4:\"3792\";s:5:\"quota\";i:1;s:9:\"activated\";i:0;s:15:\"activated_local\";i:0;s:10:\"expiration\";s:19:\"2020-06-27 10:00:00\";s:10:\"secret_key\";s:32:\"sk_I&Cicy<vyjUtE#Rd~cYWo}+;D4p_K\";s:15:\"is_whitelabeled\";b:0;s:17:\"is_free_localhost\";b:1;s:17:\"is_block_features\";b:1;s:12:\"is_cancelled\";b:0;}}}s:13:\"admin_notices\";a:1:{s:16:\"ilab-media-tools\";a:0:{}}s:7:\"updates\";a:1:{i:1431;O:13:\"FS_Plugin_Tag\":12:{s:2:\"id\";s:5:\"18751\";s:7:\"updated\";i:1593183304;s:7:\"created\";s:19:\"2020-06-26 05:18:34\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:7:\"version\";s:6:\"3.3.23\";s:3:\"url\";s:386:\"https://api.freemius.com/v1/installs/4721959/updates/18751.zip?is_premium=true&authorization=FSLA+4721959%3AiW00UNsMipIXufak3QeXd9sbagAr1QsjAJcrKDsZey3uBFSQt9BEh_ZkaMGt2e6XQSWXKpnWXoqLXjeM9MylAnaZn9DEln6QAUUPSz1qBsxQuzSparj2YBjnKPusOgZmAiQxRtU0lAc2A18Q8SkFvIT6WbV8BmNaHr5J0pfTBiH5hFsH6f6w7JUgJwmByN2S5QKL9Zuud0YHV4VGPaDmoUd1en0Y3AU06ZqHGHZhRbhe-G7v24kMWJ8zR6zD_JAhPa4MNgJ44C_dShqm807rSg\";s:25:\"requires_platform_version\";s:3:\"4.4\";s:37:\"requires_programming_language_version\";N;s:20:\"tested_up_to_version\";s:3:\"5.4\";s:8:\"has_free\";b:1;s:11:\"has_premium\";b:1;s:12:\"release_mode\";s:8:\"released\";}}}' WHERE `option_name` = 'fs_accounts'
WordPress database error: [The table 'wp_options' is full] DELETE FROM `wp_options` WHERE `option_name` = '_site_transient_wp_theme_files_patterns-1de0d11b1124cfe2057b1fd8f32658d3'
WordPress database error: [The table 'wp_options' is full] DELETE FROM `wp_options` WHERE `option_name` = '_site_transient_timeout_wp_theme_files_patterns-1de0d11b1124cfe2057b1fd8f32658d3'
WordPress database error: [The table 'wp_options' is full] UPDATE `wp_options` SET `option_value` = '1788605114.4799869060516357421875' WHERE `option_name` = '_transient_doing_cron'
Warning: Cannot modify header information - headers already sent by (output started at /var/www/clients/client0/web46/web/wp-includes/class-wpdb.php:1845) in /var/www/clients/client0/web46/web/wp-includes/feed-rss2.php on line 8 Malaria Archives - Virus Reports
https://virusreports.net/tag/malaria/
Thu, 28 May 2020 05:21:03 +0000en-US
hourly
1 https://wordpress.org/?v=6.7.7https://s3.us-west-1.wasabisys.com/virusreports/2020/05/cropped-virus-favicon-32x32.pngMalaria Archives - Virus Reports
https://virusreports.net/tag/malaria/
3232EU governments ban malaria drug for COVID-19, trial paused as safety fears grow
http://virusreports.net/eu-governments-ban-malaria-drug-for-covid-19-trial-paused-as-safety-fears-grow/
http://virusreports.net/eu-governments-ban-malaria-drug-for-covid-19-trial-paused-as-safety-fears-grow/#respondThu, 28 May 2020 05:21:03 +0000https://virusreports.net/eu-governments-ban-malaria-drug-for-covid-19-trial-paused-as-safety-fears-grow/PARIS/LONDON/MILAN (Reuters) - European governments moved on Wednesday to halt the use of anti-malaria drug hydroxychloroquine to treat COVID-19 patients, and a second global trial was suspended, further blows to hopes for a treatment promoted by U.S. President Donald Trump. The moves by France, Italy and Belgium followed a World Health Organization decision on Monday…
PARIS/LONDON/MILAN (Reuters) – European governments moved on Wednesday to halt the use of anti-malaria drug hydroxychloroquine to treat COVID-19 patients, and a second global trial was suspended, further blows to hopes for a treatment promoted by U.S. President Donald Trump.
The moves by France, Italy and Belgium followed a World Health Organization decision on Monday to pause a large trial of hydroxychloroquine due to safety concerns.
A UK regulator said on Wednesday that a separate trial was also being put on hold, less than a week after it started. The study, being led by the University of Oxford and partly funded by the Bill and Melinda Gates Foundation, was expected to involve as many as 40,000 healthcare workers.
“All hydroxychloroquine trials in COVID-19 remain under close review” while investigators assess any further risks, the Medicines and Healthcare products Regulatory Agency (MHRA) said in an email to Reuters.
The swift moves by authorities in countries hit hardest by the pandemic highlighted the challenge for governments scrambling to find ways to treat patients and control the novel coronavirus.
After early reports that it might help some patients, regulators in several countries had allowed hydroxychloroquine to be used as a potential COVID-19 treatment.
Trump was a particularly strong supporter, describing the drug as a “gamechanger.” He later announced he was taking it to prevent infection.
However, more recent studies have raised serious safety issues. British medical journal The Lancet has reported coronavirus patients receiving hydroxychloroquine were more likely to die and experience dangerous irregular heartbeats.
On Wednesday, France’s health ministry cancelled a decree in place for nearly two months that had allowed hospital doctors to dispense it in specific situations for COVID-19.
Medicines agencies in France and Italy said the drug should not be used for COVID-19 outside clinical trials. Belgium’s regulator said trials aiming to evaluate the drug should also take potential risks into consideration.
Swiss drugmaker Novartis is pushing ahead with its U.S. study involving 440 patients, while French company Sanofi declined to comment on the future of its two trials.
Italian health authorities concluded that the risks, coupled with little evidence hydroxychloroquine was beneficial against COVID-19, merited a ban outside of clinical trials.
“New clinical evidence on the use of hydroxychloroquine in subjects with SARS-CoV-2 infection … indicates an increased risk for adverse reactions with little or no benefit,” medicines agency AIFA said.
The WHO said a safety panel would evaluate by mid-June the drug’s use in its multi-country trial of potential COVID-19 treatments.
Germany is looking at The Lancet study and the WHO’s decision but has not made any decision about new guidance on hydroxychloroquine, a spokeswoman for its drugs regulator said.
The U.S. Food and Drug Administration has allowed healthcare providers to use hydroxychloroquine for COVID-19 through an emergency-use authorization, but has not approved them to treat it. It also warned in April, that for safety reasons, the drug should be used only for hospitalized COVID-19 patients or those in clinical trials.
The agency did not respond to queries asking whether it was reconsidering the emergency-use authorization.
Reporting by Matthias Blamont in Paris, Emilio Parodi in Milan, Marine Strauss in Brussels, Ludwig Burger in Frankfurt, Alistair Smout in London and Michael Erman in New York; Writing by Josephine Mason and John Miller; Editing by Mark Heinrich/Peter Graff and Grant McCool
]]>http://virusreports.net/eu-governments-ban-malaria-drug-for-covid-19-trial-paused-as-safety-fears-grow/feed/0Malaria drug touted by Trump for coronavirus fails another test
http://virusreports.net/malaria-drug-touted-by-trump-for-coronavirus-fails-another-test/
http://virusreports.net/malaria-drug-touted-by-trump-for-coronavirus-fails-another-test/#respondFri, 08 May 2020 09:21:29 +0000https://virusreports.net/malaria-drug-touted-by-trump-for-coronavirus-fails-another-test/(Reuters) - The malaria treatment repeatedly championed by U.S. President Donald Trump as a “game changer” in the fight against the novel coronavirus has again failed to show a benefit in patients hospitalized with COVID-19, according to a study released on Thursday. While the study being published in the New England Journal of Medicine had…
(Reuters) – The malaria treatment repeatedly championed by U.S. President Donald Trump as a “game changer” in the fight against the novel coronavirus has again failed to show a benefit in patients hospitalized with COVID-19, according to a study released on Thursday.
While the study being published in the New England Journal of Medicine had certain limitations, doctors reported that the use of hydroxycholoquine neither lessened the need for patients requiring breathing assistance nor the risk of death.
“We didn’t see any association between getting this medicine and the chance of dying or being intubated,” lead researcher Dr. Neil Schluger told Reuters in a telephone interview. “The patients who got the drug didn’t seem to do any better.”
Among patients given hydroxychloroquine, 32.3% ended up needing a ventilator or dying, compared with 14.9% of patients who were not given the drug.
But doctors were more likely to give hydroxychloroquine to sicker patients, so researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Center adjusted the rates to account for that. They concluded that the drug may not have hurt patients, but it clearly did not help.
Decades old hydroxychloroquine, which is also used to treat lupus and rheumatoid arthritis, also showed no benefit when combined with the antibiotic azithromycin, Schluger’s team reported. Azithromycin alone also showed no benefit.
Last month, doctors at the U.S. Department of Veterans Affairs reported that hydroxychloroquine did not help COVID-19 patients and might pose a higher risk of death.
That analysis of medical records showed a death rate of 28% when the drug was given in addition to standard treatments, compared to 11% with standard care alone.
In the latest study, 811 patients got hydroxychloroquine and 565 did not.
Because they were not randomly assigned to receive hydroxychloroquine or a placebo, “the study should not be taken to rule out either benefit or harm” for the drug, researchers said. Randomized trials, the gold standard for tests of new therapies, should continue, they added.
But for now, “the guidance in our hospital has changed so we don’t recommend giving hydroxychloroquine to hospitalized patients,” said Dr. Schluger, chief of the division of pulmonary, allergy and critical care medicine at Irving.
Smaller studies, including one done in China, had suggested hydroxychloroquine might be useful, “but these were tiny studies and not of good quality. People seized on them because patients were dying,” he said.
There are currently no approved treatments for COVID-19, although Gilead Sciences Inc’s experimental antiviral drug remdesivir last week receive emergency use authorization from U.S. regulators.
Reporting by Gene Emery in Cranston, Rhode Island; Editing by Bill Berkrot
]]>http://virusreports.net/malaria-drug-touted-by-trump-for-coronavirus-fails-another-test/feed/0Malaria ‘completely stopped’ by microbe
http://virusreports.net/malaria-completely-stopped-by-microbe/
http://virusreports.net/malaria-completely-stopped-by-microbe/#respondMon, 04 May 2020 16:50:48 +0000https://virusreports.net/malaria-completely-stopped-by-microbe/Image copyright Getty Images Image caption Malaria is spread by the bite of infected mosquitoes Scientists have discovered a microbe that completely protects mosquitoes from being infected with malaria. The team in Kenya and the UK say the finding has "enormous potential" to control the disease.Malaria is spread by the bite of infected mosquitoes, so…
Image caption
Malaria is spread by the bite of infected mosquitoes
Scientists have discovered a microbe that completely protects mosquitoes from being infected with malaria.
The team in Kenya and the UK say the finding has “enormous potential” to control the disease.
Malaria is spread by the bite of infected mosquitoes, so protecting them could in turn protect people.
The researchers are now investigating whether they can release infected mosquitoes into the wild, or use spores to suppress the disease.
What is this microbe?
The malaria-blocking bug, Microsporidia MB, was discovered by studying mosquitoes on the shores of Lake Victoria in Kenya. It lives in the gut and genitals of the insects.
The researchers could not find a single mosquito carrying the Microsporidia that was harbouring the malaria parasite. And lab experiments, published in Nature Communications, confirmed the microbe gave the mosquitoes protection.
Microsporidias are fungi, or at least closely related to them, and most are parasites.
However, this new species may be beneficial to the mosquito and was naturally found in around 5% of the insects studied.
How big a discovery is it?
“The data we have so far suggest it is 100% blockage, it’s a very severe blockage of malaria,” Dr Jeremy Herren, from the International Centre of Insect Physiology and Ecology (icipe) in Kenya told the BBC.
He added: “It will come as a quite a surprise. I think people will find that a real big breakthrough.”
More than 400,000 people are killed by malaria each year, most of them children under the age of five.
While huge progress has been made through the use of bed nets and spraying homes with insecticide, this has stalled in recent years. It is widely agreed new tools are needed to tackle malaria.
Image copyright Getty Images
Image caption
Bed nets have helped cut the number of people infected with malaria around the world
How does the microbe stop malaria?
The fine details still need to be worked out.
But Microsporidia MB could be priming the mosquito’s immune system, so it is more able to fight off infections.
Or the presence of the microbe in the insect could be having a profound effect on the mosquito’s metabolism, making it inhospitable for the malaria parasite.
Microsporidia MB infections appear to be life-long. If anything, the experiments show they become more intense, so the malaria-blocking effect would be long-lasting.
When can this be used against malaria?
At the very least, 40% of mosquitoes in a region need to be infected with Microsporidia in order to make a significant dent in malaria.
The microbe can be passed between adult mosquitoes and is also passed from the female to her offspring.
So, the researchers are investigating two main strategies for increasing the number of infected mosquitoes.
Microsporidia form spores which could be released en masse to infect mosquitoes
Male mosquitoes (which don’t bite) could be infected in the lab and released into the wild to infect the females when they have sex
“It’s a new discovery. We are very excited by its potential for malaria control. It has enormous potential,” Prof Steven Sinkins, from the MRC-University of Glasgow Centre for Virus Research, told the BBC.
This concept of disease control using microbes is not unprecedented. A type of bacteria called Wolbachia has been shown to make it harder for mosquitoes to spread dengue fever in real-world trials.
What happens next?
The scientists need to understand how the microbe spreads, so they plan to perform more tests in Kenya.
However, these approaches are relatively uncontroversial as the species is already found in wild mosquitoes and is not introducing something new.
It also would not kill the mosquitoes, so would not have an impact on ecosystems that are dependent on them as food. This is part of other strategies like a killer fungus that can almost completely collapse mosquito populations in weeks.
]]>http://virusreports.net/malaria-completely-stopped-by-microbe/feed/0World Malaria Day: Would Coronavirus Restore or Hinder India’s Success Story Versus Malaria?
http://virusreports.net/world-malaria-day-would-coronavirus-restore-or-hinder-indias-success-story-versus-malaria/
http://virusreports.net/world-malaria-day-would-coronavirus-restore-or-hinder-indias-success-story-versus-malaria/#respondSun, 26 Apr 2020 09:29:15 +0000https://virusreports.net/world-malaria-day-would-coronavirus-restore-or-hinder-indias-success-story-versus-malaria/WHO has warned that the deaths from malaria could double this year to nearly 8 lakh in sub-Saharan Africa if anti-malarial campaigns are suspended and supply of medicines is disrupted due to COVID-19 and related lockdowns. Even in India, the lockdown has restricted the movement of Accredited Social Health Activists (ASHA), who reach out to…
]]>WHO has warned that the deaths from malaria could double this year to almost 8 lakh in sub-Saharan Africa if anti-malarial campaigns are suspended and supply of medicines is disrupted due to COVID-19 and related lockdowns.
Even in India, the lockdown has actually restricted the motion of Accredited Social Health Activists (ASHA), who reach out to the most remote parts of India and supply vital early detection and treatment at the neighborhood level. As the lockdowns reach more than a month, production and supply of important malaria commodities like long-lasting insecticidal webs, fast diagnostic tests and antimalarial medicines like hydroxychloroquine, have taken a hit. The WHO’s warnings specifically highlight these issues and urge nations to act quickly to prevent losing the gains made in conserving lives from malaria over the past 20 years.
” Making sure access to core malaria avoidance measures is a crucial technique for decreasing the strain on health systems; these include vector control steps, such as insecticide-treated webs and indoor residual spraying, along with chemoprevention for pregnant females and children. Extra unique procedures might relieve the problem on health systems in the context of COVID-19, such as presumptive malaria treatment and mass drug administration,” says WHO.
Structure upon India’s success story
Representational image
( MALARIA NO MORE)
The COVID-19 pandemic, while posing a significant danger, likewise provides an opportunity to win the fight against malaria. The illness security programs at the grass-root level targeted towards the novel coronavirus could include malaria-related services as well and such techniques can yield co-benefits against both deadly diseases. At the exact same time, the destruction brought on by COVID-19 could amplify numerous times if its reaction undermines the life-saving services of other health problems.
WHO likewise recommends particular remarkable steps, such as presumptive treatment and mass drug administration, at a few vulnerable locations. Under these methods, a sensitive population is treated despite whether they reveal signs. The security of health employees ought to likewise be ensured while executing such steps.
A truly screening time has actually come for the nations with the malaria burden– a test of whether we can act now to build on years of effort and success or undo it due to our short-sightedness.
There is hope! In the most-vulnerable states like Odisha, the malaria programs are at-the-ready for a reboot as soon as the lockdown is raised. “Insecticide-treated mosquito nets have actually currently been distributed and all preparations for the pre-monsoon accumulation of anti-malaria activities in states like Odisha are in location. If these activities could start right away after the lockdown is lifted and before the beginning of monsoon rains in early June, India’s development versus malaria can be preserved,” states Dr Gaikwad.
In general, specialists believe that with sufficient preparation, the response to the COVID-19 pandemic can save lives, strengthen the health care systems to attend to malaria and other contagious diseases better and lower the problem on already challenged healthcare systems. With a number of brand-new barriers as we advance, a malaria-free India stays a far-off, yet achievable dream. World Malaria Day 2020 is here to remind us not to lose sight of this ultimate objective.
( with inputs from Malaria No More)
For COVID-19, weather condition & air quality updates on the go, download The Weather Condition Channel App(on Android and iOS shop). It’s totally free!
]]>http://virusreports.net/world-malaria-day-would-coronavirus-restore-or-hinder-indias-success-story-versus-malaria/feed/0New vaccine for malaria
http://virusreports.net/new-vaccine-for-malaria/
http://virusreports.net/new-vaccine-for-malaria/#respondSun, 26 Apr 2020 08:23:07 +0000https://virusreports.net/new-vaccine-for-malaria/On a sunny morning outside a hospital in western Kenya, 20 or so mothers sit on wooden benches with babies in their arms. Wrapped in colorful blankets and kitenge pattern cloths, one by one the babies are injected with a shot. And one by one, they cry. Pole baby—sorry, baby—says the nurse. But the prick…
On a sunny morning outside a hospital in western Kenya, 20 or so mothers sit on wooden benches with babies in their arms. Wrapped in colorful blankets and kitenge pattern cloths, one by one the babies are injected with a shot. And one by one, they cry. Pole baby—sorry, baby—says the nurse. But the prick is worth the pain: These babies are among the earliest to receive the first-ever vaccine against malaria, one of the deadliest diseases in the world.
Hundreds of thousands of children across malaria-stricken regions of Kenya, Malawi, and Ghana are receiving the RTS,S malaria vaccine, which Western health experts laud as an exciting new tool in the global fight against the disease. But after 35 years and hundreds of millions of dollars spent in development, some African health professionals are wondering: Is the vaccine worth the cost?
View Images
Women wait at Iguhu District Hospital in western Kenya so that their babies can receive the malaria vaccine. In Africa, about 285,000 children died before their fifth birthdays in 2016.
Each year malaria sickens some 228 million people and kills 430,000, most of them in Africa, and most of them children. Spread by female Anopheles mosquitoes, the parasite that causes malaria leads to fevers, lethargy, and chills. It can keep adults bedridden for weeks, take children out of school, and saddle families with crippling medical costs. (See what makes mosquitoes such deadly creatures.)
Violet Wachiya, 24, was one such case. Born into a rural western Kenyan household that farmed sugarcane and raised livestock, at 12 she dropped out of school after an extreme bout of malaria left her hospitalized. She was fatigued, her joints ached, and soon her eyesight became impaired. “I couldn’t see clearly,” she says. The hospital bill came to 34,000 Kenyan shillings (about $320). To pay it, her family sold four of their eight cows and some of their goats.
View Images
Two girls cut grass in a watery field in Kakamega County, Kenya. Malaria is spread by female Anopheles mosquitos, which breed in stagnant water and proliferate during the rainy season.
Wachiya says she doesn’t want the same thing to happen to her son, 10-month-old Prince Jackson, which is why last month she swaddled him in a blue-and-white sweatshirt and carried him to a hospital in rural Kakamega County to receive his second dose of the new malaria vaccine. (Children receive the first of four doses at six months old, and the final at two years.) Now, “even if the baby gets malaria it won’t be as bad,” says Wachiya.
After Prince Jackson gets his injection, Wachiya carries him home to their village surrounded by sugarcane fields. Inside their small house, Luya music plays from a speaker while an arcade machine flashes colorful lights and periodically plays Shakira’s Waka Waka, the theme song of the 2006 World Cup in South Africa. A chair rests in front of a grey concrete wall where Wachiya styles the hair of neighborhood women and where her husband, painter and barber Vincent Olang’, gives children buzzcuts for 10 shillings (10 cents) each.
View Images
Ten-month-old Prince Jackson sleeps under a mosquito net at his home in Kakamega County, Kenya. He’s received two of the four doses of malaria vaccine so far.
At night the family retires to the bedroom, crawls under a blue mosquito net, and sleeps on a mattress on the floor. The net protects them from the audible swarm of mosquitoes buzzing around the pit latrine out back.
“They make so much noise they sound like bees,” says Olang’. He walks across his family’s small plot of farmland to reveal a swamp just behind the house. “After water overflows from the river, then we have stagnant water—and that brings mosquitos,” he explains. (Here’s how mosquitos survive the dry season.)
In an attempt to drain the stagnant water, Vincent’s uncle, Benson Musotsi, dug a deep trench across the plot, but to little effect. He hopes the new malaria vaccine will do more to protect the people of Kakamega County. “Once having been vaccinated, definitely you can’t get malaria,” says Musotsi. “If the mosquito bites you, it can’t give it to you.”
View Images
Vincent Olang’ and Violet Wachiya fetch water from a small river near their house. They’ve tried to drain the stagnant water to discourage mosquitos from breeding there, but with little success.
But Musotsi may be mistaken. In clinical trials the RTS,S vaccine decreased malaria cases by 39 percent and severe cases by 29 percent. In contrast, vaccines for most other diseases are over 85 to 95 percent effective. The new vaccine is even less effective if children don’t receive all four doses, which can be a challenge for many rural families who live far from heath facilities.
Over the past 20 years global anti-malaria initiatives prevented more than 663 million cases, saved 6.8 million lives, and reduced healthcare costs by nearly a billion dollars in sub-Saharan Africa alone, according to the World Health Organization (WHO). But none of that was due to a vaccine. Rather, the credit goes to insecticide spraying, bed nets, and anti-malarial drugs.
One study estimated that the malaria vaccine will be nearly three times as expensive, on average, as distributing bed nets to achieve the same improvements in health. With limited funding available, some health professionals in Kenya worry that the money is being misspent.
View Images
A research assistant offers his hand to a group of female mosquitos during a fresh blood feeding at the Kenya Medical Research Institute, where scientists are studying insecticide-resistant mosquitos.
Four-year-old Sheila Musungu lays on a cot in a crowded hospital ward, barely moving, barely awake. Mosquitoes buzz around her. “She isn’t eating,” says her mother. “She’s been vomiting. Tired.”
Sheila contracted malaria while she was in the hospital. Her mother brought her here in January for a blood transfusion, but because she couldn’t pay the bill, Sheila was forced to stay for months—on a cot with no mosquito net. If she’d had one, it likely would have protected her from malaria. None of the other 20 or so patients in the ward have nets either.
“I’ve been here for two years, and for two years we have not had the nets,” says the on-duty nurse, 28-year-old Petronilla Buyaki. Kenyan health officials say that international donors had promised to give out the nets for free but didn’t deliver.
View Images
Four-year-old Sheila Musungu came down with malaria at Kakamega Teaching and Referral Hospital, where she had originally gone for a blood transfusion in January.
Mosquito nets cost about $5 on the local market. That’s the amount Sheila’s medical bill goes up each day. Her family now owes the hospital more than 27,000 Kenyan shillings (about $250). Until they pay, Sheila will continue lying there, unprotected from mosquitoes, day after day.
To be sure, nets alone will not end malaria. Unlike Sheila, most people can’t stay under them all day.Besides, says Desmond Chavasse, who works on malaria control in Kenya for the NGO PSI, “We’ve already harvested most of the benefits you can expect to harvest” from nets. That’s due to what many in international development refer to as the “last mile” problem—the increasing difficulty of bringing a health intervention to the last, most remote people. He says new tools, like a vaccine, are needed to bridge the gap.
Health workers like Buyaki say they’ll take any help they can get. “Almost every other case is a malaria case here,” says Buyaki as she looks around her ward. A vaccine would be welcome, but she’d be thankful just to have a few dozen of the cheap, effective prevention devices that already exist. “The nets—that’s our need, for now.”
View Images
Two girls stand in front of a house in Kakamega County, Kenya. Children are at a higher risk of succumbing to malaria because they have less immunity.
In 1972Chinese scientists discovered Artemisinin, a drug now used across the world to treat malaria and has saved millions of lives. Now, some Chinese scientists believe Artemisinin Combination Therapies (ACTs) can be harnessed for a new purpose: to prevent malaria. By giving ACTs to an entire community at once, a process called Mass Drug Administration (MDA), scientists can reduce the levels of the malaria parasite in human blood so that mosquitoes won’t contract it and spread it to the next person.
“The life cycle for a mosquito is 30 days,” explains Ethan Peng, Senior Manager in Kenya for the Chinese company New South, which manufactures ACTs. “So by mass medication, we can clear the source from all human beings (so) the mosquitoes cannot pick up the malaria parasite again” within their short lifespan.
Already, Chinese scientists have used MDA to eliminate malaria on three of the four islands that make up the African nation of Comoros.
View Images
Private clinics like Cheldeb Medical Center in Kakamega, Kenya account for the majority of anti-malaria treatment in the country, though they are more likely than public hospitals to run out of tests.
“Elimination is quite new” as a concept, says Rebecca Kiptui, who worked with New South to develop a MDA trial in Kenya on behalf of Kenya’s National Malaria Control Program. “The question is, can MDA be done in an area where [malaria] is endemic? Can this model be replicated elsewhere?”
Kim Lindblade of the WHO’s Global Malaria Program says replicating Comoros’ success on the African mainland is unlikely. “We don’t have a story like that anywhere else. Why? Because it’s an island,” says Lindblade. “If it’s going to work anywhere, it’s going to work there.”
What scientists do agree on is that unless they develop new ways to stop the disease, progress against malaria won’t just slow. It will reverse. That’s because the malaria parasite is becoming resistant to the drugs and insecticides used to treat it. Resistance has already contributed to an increase in the disease in Africa and Asia. In 2018 Kenya saw 11 million malaria cases—up from 8 million the year before.
“Some of the mutations that have been seen in southeast Asia we have seen in western Kenya,” says Dr. Bernhards Ogutu, a malaria researcher for the Kenya Medical Research Institute. “In a matter of time, if you get one or two more mutations…” he throws up his hands in concern. “People don’t want to change from the current ways of doing things. But if we continue to do things the way we are, in eight years we’ll even get an increase in the disease.”
The race to eradicate is on, says Ogutu. “We have to get out of the mode of waiting for a sick patient” and begin working to eradicating malaria entirely. But that will take more money. The WHO’s goal is to reduce malaria by 90 percent worldwide by 2030, but according to a study last year in the Lancet, that will require an additional $2 billion beyond the $4.3 billion currently spent each year.
For their part, when it comes to protecting themselves from malaria, Mutosi and his family aren’t putting all their eggs in one basket.
“There is a time when the vaccine will start diminishing,” Musotsi surmises. “So the net will still protect you.”
Reporting for this story was funded by a grant from the European Journalism Centre.
Lena Mucha is a Berlin-based German photographer who focuses on human rights, gender aspects and social changes within societies and ethnic groups that are mainly underreported.
Jacob Kushner is a foreign correspondent who writes about health, wildlife, migration, and human rights from Africa, Germany, and the Caribbean.
]]>http://virusreports.net/new-vaccine-for-malaria/feed/0Battle versus malaria might be held up 20 years, WHO warns
http://virusreports.net/battle-versus-malaria-might-be-held-up-20-years-who-warns/
http://virusreports.net/battle-versus-malaria-might-be-held-up-20-years-who-warns/#respondSat, 25 Apr 2020 20:23:32 +0000https://virusreports.net/battle-versus-malaria-might-be-held-up-20-years-who-warns/CAPE TOWN, South Africa (AP) — One of the hard lessons the World Health Organization learned during the Ebola outbreak in West Africa was this: Other diseases can be forgotten and take a deadlier toll.The WHO is now warning that the battle against malaria in sub-Saharan Africa, where it already kills hundreds of thousands of…
CAPE TOWN, South Africa (AP)– Among the difficult lessons the World Health Organization discovered during the Ebola break out in West Africa was this: Other illness can be forgotten and take a deadlier toll.
The WHO is now warning that the fight against malaria in sub-Saharan Africa, where it currently eliminates hundreds of thousands of individuals a year, could be held up by 20 years as nations focus energy and resources on consisting of the coronavirus.
The WHO stated new projections show that in a worst-case circumstance, 769,000 individuals might die of malaria in sub-Saharan Africa this year as projects to fight it are disturbed. That’s more than double the deaths in the last detailed count two years back, when more than 360,000 individuals died, and would be the worst figures for the area since2000
” We should not reverse the clock,” Matshidiso Moeti, WHO regional director for Africa, stated Thursday.
While health professionals express worries that the coronavirus pandemic could deteriorate the global fight against lots of diseases, sub-Saharan Africa is by far the worst affected by malaria. It had 93%of the world’s cases and 94%of deaths in 2018, the WHO said. The deaths were primarily kids under the age of 5.
There have actually currently been “severe disturbances” to anti-malaria campaigns and access to anti-malaria medication in Africa, WHO said.
The caution came ahead of World Malaria Day on Saturday. Malaria stays one of the leading killers in low-income nations.
” I advise all countries to not lose focus on their gains made in health as they adapt to tackle this brand-new risk,” Moeti said. “We saw with the Ebola virus disease outbreak in West Africa that we lost more individuals to malaria, for example, than we lost to the Ebola outbreak. Let us not duplicate that with COVID-19”
Africa has reported more than 27,000 cases of COVID-19 and almost 1,300 deaths, according to the Africa Centers for Illness Control and Prevention. The continent is at a point in the break out that more than one health specialist has actually described as the calm before the storm.
” This means that nations throughout the region have a vital window of opportunity to minimize interruptions in malaria prevention and treatment and conserve lives,” WHO said in a statement targeted at highlighting the hazard malaria still presents.
Malaria isn’t the only issue.
Immunization campaigns to secure kids against measles, polio and yellow fever are likewise affected, and not simply in Africa.
Earlier this month, the Measles and Rubella Initiative stated more than 24 nations including South Sudan, Mexico and Bangladesh had suspended immunizations, which figure might rise to37 More than 117 million children may lose out on receiving perhaps life-saving vaccines for measles, which has actually seen a revival in the last few years.
Perhaps the most alarming suspension of an immunization program has occurred in Congo, where more than 6,000 individuals have passed away in the world’s biggest present measles break out. The outbreak has lasted over a year, a profoundly discouraging development for health authorities given that a vaccine was established more than 50 years ago.
]]>http://virusreports.net/battle-versus-malaria-might-be-held-up-20-years-who-warns/feed/0Battle against malaria might be held up twenty years, WHO warns
http://virusreports.net/battle-against-malaria-might-be-held-up-twenty-years-who-warns/
http://virusreports.net/battle-against-malaria-might-be-held-up-twenty-years-who-warns/#respondSat, 25 Apr 2020 08:24:10 +0000https://virusreports.net/battle-against-malaria-might-be-held-up-twenty-years-who-warns/The World Health Organization is warning that the battle against malaria in sub-Saharan Africa could be set back by 20 years as countries focus energy and resources on containing the coronavirusBy GERALD IMRAY Associated PressApril 24, 2020, 11:46 AM3 min readCAPE TOWN, South Africa -- One of the hard lessons the World Health Organization learned…
The World Health Organization is alerting that the fight versus malaria in sub-Saharan Africa might be set back by 20 years as countries focus energy and resources on containing the coronavirus
By
GERALD IMRAY Associated Press
April 24, 2020, 11: 46 AM
3 minutes read
CAPE TOWN, South Africa–
One of the hard lessons the World Health Company found out during the Ebola break out in West Africa was this: Other diseases can be forgotten and take a deadlier toll.
The WHO is now alerting that the fight against malaria in sub-Saharan Africa, where it currently kills hundreds of thousands of people a year, could be held up by 20 years as countries focus energy and resources on containing the coronavirus.
The WHO said brand-new projections suggest that in a worst-case circumstance, 769,000 people might die of malaria in sub-Saharan Africa this year as campaigns to combat it are interrupted. That’s more than double the deaths in the last in-depth count 2 years earlier, when more than 360,000 individuals died, and would be the worst figures for the region given that2000
” We should not reverse the clock,” Matshidiso Moeti, WHO local director for Africa, said Thursday.
While health professionals reveal fears that the coronavirus pandemic might wear down the global fight versus lots of diseases, sub-Saharan Africa is without a doubt the worst impacted by malaria. It had 93%of the world’s cases and 94%of deaths in 2018, the WHO said. The deaths were generally kids under the age of 5.
There have already been “extreme disturbances” to anti-malaria campaigns and access to anti-malaria medication in Africa, WHO said.
The warning came ahead of World Malaria Day on Saturday. Malaria remains among the leading killers in low-income nations.
” I urge all nations to not lose focus on their gains made in health as they adjust to tackle this new risk,” Moeti said. “We saw with the Ebola infection illness outbreak in West Africa that we lost more individuals to malaria, for instance, than we lost to the Ebola break out. Let us not duplicate that with COVID-19”
Africa has actually reported more than 27,000 cases of COVID-19 and almost 1,300 deaths, according to the Africa Centers for Disease Control and Avoidance. The continent is at a point in the outbreak that more than one health expert has described as the calm before the storm.
” This indicates that countries across the region have an important window of opportunity to reduce disturbances in malaria prevention and treatment and save lives,” WHO said in a declaration focused on highlighting the threat malaria still presents.
Malaria isn’t the only concern.
Immunization campaigns to protect children against measles, polio and yellow fever are also impacted, and not just in Africa.
Previously this month, the Measles and Rubella Effort stated more than 24 countries consisting of South Sudan, Mexico and Bangladesh had suspended immunizations, which figure could rise to37 More than 117 million children might miss out on getting perhaps life-saving vaccines for measles, which has actually seen a revival over the last few years.
Perhaps the most worrying suspension of an immunization program has actually occurred in Congo, where more than 6,000 people have actually passed away on the planet’s largest present measles outbreak. The outbreak has lasted over a year, an exceptionally aggravating development for health officials given that a vaccine was developed more than 50 years ago.
]]>http://virusreports.net/battle-against-malaria-might-be-held-up-twenty-years-who-warns/feed/0WHO warns malaria deaths in Africa could double amid pandemic
http://virusreports.net/who-warns-malaria-deaths-in-africa-could-double-amid-pandemic/
http://virusreports.net/who-warns-malaria-deaths-in-africa-could-double-amid-pandemic/#respondFri, 24 Apr 2020 16:21:51 +0000https://virusreports.net/who-warns-malaria-deaths-in-africa-could-double-amid-pandemic/The World Health Organisation (WHO) has warned that the number of deaths caused by malaria in sub-Saharan Africa could double to 769,000, as efforts to tackle the disease face disruptions by the coronavirus pandemic. As of Thursday, the region had registered more than 26,000 cases of COVID-19, the highly infectious respiratory disease caused by the…
The World Health Organisation (WHO) has warned that the number of deaths caused by malaria in sub-Saharan Africa could double to 769,000, as efforts to tackle the disease face disruptions by the coronavirus pandemic.
As of Thursday, the region had registered more than 26,000 cases of COVID-19, the highly infectious respiratory disease caused by the new coronavirus. Some 7,000 people have so far recovered, while almost 1,250 have died.
At a media briefing, WHO Regional Director for Africa Matshidiso Moeti urged all countries to ensure that essential malaria prevention work continues during the coronavirus pandemic.
“A recent analysis has found that if insecticide-treated bed net distribution stops, and case management reduces, malaria deaths in sub-Saharan Africa could double in comparison to 2018,” Moeti said on Thursday.
“This would be the highest number of deaths seen in the region since the year 2000.”
Dr @MoetiTshidi urges all countries in Africa to maintain malaria interventions during the #COVID19 pandemic at today’s @WHO media briefing with @WEF. Keeping up prevention and treatment will ensure that health workers and communities are protected. pic.twitter.com/x7wtbE83Yy
— WHO African Region (@WHOAFRO) April 23, 2020
Malaria is a life-threatening mosquito-borne disease that often causes fever, chills and flu-like symptoms. It is a treatable disease if it is caught early, but current antimalarial drugs are failing in many areas due to increasing drug resistance.
In 2018, there were 213 million malaria cases and 360,000 related deaths in the African region, accounting for more than 90 percent of cases worldwide.
The WHO said that if the focus on slowing the spread of the new coronavirus leads to a 75 percent reduction in access to anti-malaria medicines, deaths could double to 769,000. Such a scenario would have devastating consequences for young children, with those under five making up more than two-thirds of all malaria deaths in 2018.
The global health agency called on countries in sub-Saharan Africa – where nearly 95 percent of all the world’s malaria cases and deaths occur – to distribute malaria prevention and treatment tools now, before they become overwhelmed with COVID-19 cases.
“Countries across the region have a critical window of opportunity to minimise disruptions in malaria prevention and treatment and save lives at this stage of the COVID-19 outbreak,” the WHO said in a statement.
The doubling of the number of deaths represents the worst-case scenario, which also assumes the suspension of all distribution of treated mosquito nets due to the pandemic, the global health agency added.
Moeti cited figures from Africa’s Ebola outbreak showing that more people died of other diseases, including malaria, than from Ebola itself, due to lack of access to treatment.
“Let us not repeat that again with COVID-19,” she said.
In a separate statement on Thursday, the WHO also repeated a call to maintain immunization services worldwide to ensure the measures taken to halt the pandemic do not end up sparking a resurgence of vaccine-preventable diseases such as measles and polio.
“While the world strives to develop a new vaccine for COVID-19 at record speed, we must not risk losing the fight to protect everyone, everywhere against vaccine-preventable diseases,” WHO chief Tedros Adhanom Ghebreyesus said in the statement.
“These diseases will come roaring back if we do not vaccinate.”
]]>http://virusreports.net/who-warns-malaria-deaths-in-africa-could-double-amid-pandemic/feed/0Utah has already ordered $800K of malaria drugs, could spend millions more on unproven COVID-19 treatment
http://virusreports.net/utah-has-already-ordered-800k-of-malaria-drugs-could-spend-millions-more-on-unproven-covid-19-treatment/
http://virusreports.net/utah-has-already-ordered-800k-of-malaria-drugs-could-spend-millions-more-on-unproven-covid-19-treatment/#respondFri, 24 Apr 2020 14:26:58 +0000https://virusreports.net/utah-has-already-ordered-800k-of-malaria-drugs-could-spend-millions-more-on-unproven-covid-19-treatment/state health officials have been pondering in recent weeks. Officials say their idea is to procure the medicine for 200,000 coronavirus patients and distribute it to drug stores across the state, where it would be available at no cost to people with a prescription certifying their COVID-19 diagnosis. Health experts consulted by the state discouraged…
]]>state health officials have been pondering in recent weeks. Officials say their idea is to procure the medicine for 200,000 coronavirus patients and distribute it to drug stores across the state, where it would be available at no cost to people with a prescription certifying their COVID-19 diagnosis.
Health experts consulted by the state discouraged the purchase, saying that “there is no rationale for the state to expend precious resources” without any solid evidence that the medication helps coronavirus patients.
The state’s objective was to prevent any shortages of the drug, which are often prescribed to people with lupus and rheumatoid arthritis. But on Thursday, health officials released a statement that suggested this threat might be subsiding.
“The most consistent element of COVID-19 has been that things are constantly changing,” said Jeff Burton, acting executive director of the Utah Department of Health. “We wanted to put ourselves in a position that if there were to be a shortage in the supply chain of hydroxychloroquine we were well-positioned to be able to provide medication to Utah residents who need it. The good news is, the supply chain has recently shown signs of stabilization.”
Health officials said they are still researching federal requirements about the compounding and distribution of hydroxychloroquine and have not yet signed a contract for the 200,000 courses of treatment.
A purchase order obtained by The Salt Lake Tribune shows the state’s purchasing division requested 20,000 doses of the malaria drugs from Meds in Motion on March 31 — about 10 days after state leaders and business representatives held a news conference where one doctor declared the medicine had pulled some coronavirus patients back from the brink of death like Lazarus of the Bible.
It’s not clear what the state has done with this stash of medication, how the purchase was arranged or what the source of funding was.
The order happened a couple weeks before the Legislature passed SB3001, a spending bill that set aside $2 million for a drug stockpile. Lawmakers on Thursday were considering another proposal to reserve an additional $6 million in federal funds for medication. Specific expenditures for the drugs were not spelled out in the language of either bill.
Rep. Brad Last, House chairman of the Legislature’s main budget committee and sponsor of the proposal considered Thursday, HB4001, said the money could go toward hydroxychloroquine or any other treatment that ends up showing promise.
“These funds are going to be set aside for potential treatments, and we might not even know what they are at this time,” said Last, R-Hurricane.
Last told his colleagues that the state bought the initial 20,000 doses of hydroxychloroquine and chloroquine after the federal government warned of potential drug scarcities. He also argued that the $6 million appropriation was a “fairly small amount” of the roughly $1.3 billion in federal funds expected to flow to Utah.
His colleague, Rep. Suzanne Harrison, agreed and said the state’s drug acquisition efforts so far have troubled her.
“I have concerns that this lack of transparency is just enriching certain companies, potentially, and I just urge caution and fiscal responsibility,” said Harrison, D-Draper, a physician anesthesiologist.
However, Last resisted the change, saying it could hamper the state’s ability to adapt to a situation in flux, and House lawmakers narrowly rejected Ward’s amendment before passing the overall bill. The Senate later signed off on the proposal, sending it to the governor’s desk.
Alliance for a Better Utah, a government accountability and progressive advocacy group, condemned the $6 million appropriation in a Thursday evening statement.
“At a time when Utah hospitals are depending on volunteers to sew medical masks for health care workers on the front lines, it is unconscionable that state leaders are choosing to blow public money in this way,” Chase Thomas, the alliance’s executive director, said in the statement. “Public funds should not be used to bail out a private business gamble, nor should public funds be used to purchase an unproven drug against the advice of medical professionals.”
The owner of Meds in Motion, Dan Richards, has established a relationship with Senate President Stuart Adams. Both of them are part of an informal group of officials and businesspeople that formed to discuss testing and treatment options during the pandemic.
Adams, R-Layton, has supported stocking up on the medicine and participated in talks about buying it from Richards’ company.
“If it does work and we don’t have any of it and it will save people’s lives, what a travesty,” Adams told reporters Thursday. “And if it doesn’t work and we’ve expended a few dollars, well, it might be a travesty but I don’t think the dollars will equate to the lives, perhaps, that may have been lost.”
However, health experts in Utah have warned that the drug has no proven benefit to coronavirus patients and could be dangerous to some.
On Tuesday, news broke about a study of 368 Veterans Affairs (V.A.) patients with coronavirus found that those who took the medicine, hydroxychloroquine, had higher rates of death than those who did not. There was no apparent benefit from the drug.
It was not a rigorous experiment and hasn’t been peer-reviewed. However, according to the Associated Press, the study is larger than others that have attempted to explore the drug’s potential for treating COVID-19.
In an interview about the V.A. study, Burton said he was reviewing the information but didn’t expect it would derail the deal with Meds in Motion.
“At this point, there would have to be a lot more information to come in that would cause us to not want to proceed,” Burton said Wednesday.
Infectious disease experts in Utah and elsewhere have argued that coronavirus patients should only use hydroxychloroquine — which has been approved by the FDA but not for COVID-19 — inside of a clinical trial so researchers can gather data about its effectiveness. In rare cases, the drug can cause dangerous heart rhythm problems, and physicians studying it in Utah say they are carefully monitoring patients using the medication.
]]>http://virusreports.net/utah-has-already-ordered-800k-of-malaria-drugs-could-spend-millions-more-on-unproven-covid-19-treatment/feed/0How Malaria Detecting Dogs Could Help Battle Coronavirus
http://virusreports.net/how-malaria-detecting-dogs-could-help-battle-coronavirus/
http://virusreports.net/how-malaria-detecting-dogs-could-help-battle-coronavirus/#respondFri, 17 Apr 2020 00:49:20 +0000http://virusreports.net/how-malaria-detecting-dogs-could-help-battle-coronavirus/Need help? Contact us We've detected unusual activity from your computer network To continue, please click the box below to let us know you're not a robot. Why did this happen? Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review…
We’ve detected unusual activity from your computer network
To continue, please click the box below to let us know you’re not a robot.
Why did this happen?
Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy.
Need Help?
For inquiries related to this message please contact our support team and provide the reference ID below.
